Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models

Antibody-drug conjugates (ADCs) are a promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to capture patients who might benefit from specific AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Supreet, Fang, Lei, McGowen, Kerry, Yin, JuanJuan, Bowman, Joel, Ku, Anson T., Alilin, Aian Neil, Corey, Eva, Roudier, Martine P., True, Lawrence D., Dumpit, Ruth, Coleman, Ilsa, Lee, John K., Nelson, Peter S., Capaldo, Brian J., Mariani, Aida, Hoover, Clare, Senatorov, Ilya S., Beshiri, Michael, Sowalsky, Adam G., Hurt, Elaine M., Kelly, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645377/
https://www.ncbi.nlm.nih.gov/pubmed/37725435
http://dx.doi.org/10.1172/JCI162148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645377/
https://www.ncbi.nlm.nih.gov/pubmed/37725435
http://dx.doi.org/10.1172/JCI162148

Ejemplares similares